There is considerable interest in exploiting metallosupramolecular cages as drug delivery vectors. Recently, we developed a [Pd2L4] 4+ cage capable of binding two molecules of cisplatin. Unfortunately, this first generation cage was rapidly decomposed by common biologically revelant nucleophiles. In an effort to improve the kinetic stability of these cage architectures here we report the synthesis of two amino substituted tripyridyl 2,6-bis(pyridin-3-ylethynyl)pyridine ( C and DOSY NMR spectroscopies, high resolution electrospray mass spectrometry, elemental analysis and, in several cases, by X-ray crystallography. It was established, using model palladium(II) N-heterocyclic carbene (NHC) probe complexes, that the amino substituted compounds were stronger donor ligands than the parent system (2A-tripy > 3A-tripy > tripy). Competition experiments with a range of nucleophiles showed that these substitutions lead to more kinetically robust cage architectures, with [Pd2(2A-tripy)4] 4+ proving the most stable. Biological testing on the three ligands and cages against A549 and MDA-MB-231 cell lines showed that only [Pd2(2A-tripy)4] 4+ exhibited any appreciable cytotoxicity, with a modest IC50 of 36.4  1.9 µM against the MDA-MB-231 cell line. Unfortunately, the increase in kinetic stability of the [Pd2(Ltripy)4] 4+ cages was accompanied by loss of cisplatin-binding ability.
Introduction
Interest in self-assembled coordination complexes of welldefined two-and three-dimensional geometries, or metallosupramolecular architectures, 1 continues to grow due to their potential in a range of applications. The molecular recognition properties of these systems have been used to develop molecular reactions flasks, 2 catalysts 3 and drug delivery agents. 4 Systems have also been used to sequester reactive species, 5 and environmental pollutants. 6 Additionally, the biological, 7 photophysical, 8 electronic 9 and redox 10 properties of these metallosupramolecular architectures have been studied.
As part of our interest in the biological properties 11 of metallosupramolecular architectures we have previously reported the synthesis of a tripyridyl (tripy) [Pd2L4] 4+ cage capable of binding cisplatin (cis-[Pt(NH3)2Cl2]). 11d We hoped to exploit these [Pd2L4] 4+ cages as metallosupramolecular drug delivery vectors, unfortunately the cage architecture was rapidly decomposed when exposed to chloride (Cl -), 11a, 11d, 12 histidine (his) 11a and cysteine (cys) 11a (common nucleophiles in biological systems). In order to use these cisplatin binding
[Pd2L4] 4+ cages as drug delivery agents a method for increasing the kinetic stability of these metallosupramolecular architectures against nucleophiles was required. 13 There are two obvious approaches to enhance the kinetic stability of the cage architectures: 1) assemble the cage using more kinetically inert metal ions or 2) sterically and electronically tune the tripy ligand framework. Exploiting kinetically inert metals for the generation of metallosupramolecular architectures can be difficult due to the formation of kinetically "trapped" intermediate structures that cannot "error-correct" into the desired system. Therefore we chose to generate more electrondonating tripyridyl ligands in an effort to obtain more kinetically robust [Pd2L4] 4+ cages. Herein we report the synthesis of two new amino substituted tripyridyl ligands (2A-tripy and 3A-tripy) and their respective cages (Scheme 1). The addition of the amino groups to the 2-and 3-positions of the terminal ligating pyridyl units of the ligand framework was expected to increase the donor properties of the ligands and lead to more kinetically robust cage architectures. Additionally, the presence of the 2-amino units within the [Pd2(2A-tripy)4] 4+ cage architecture was expected to sterically reduce access to the palladium(II) ions potentially further enhancing the cage lifetime in the presence of biological nucleophiles. Competition experiments with Cl -, his and cys nucleophiles showed that the [Pd2(2A-tripy)4] 4+ cage was more stable than the [Pd2(3A-tripy)4] 4+ cage which in turn was more stable than the [Pd2(tripy)4] 4+ cage. Unfortunately, the structural and electronic changes imposed through amino substitution in the 2-position circumscribe the ability of the cage to encapsulate cisplatin. Preliminary biological testing on these systems indicated that only [Pd2(2A-tripy)4] 4+ exhibited an IC50 < 50 µM against either of the two investigated cell lines.
Results and Discussion

Synthesis and Characterisation
The electronically and sterically tuned tripyridyl ligands (tripy, 2A-tripy, and 3A-tripy, Scheme 1) were synthesised using standard methods 11d, 12, 14 (ESI †) and characterised using NMR spectroscopy, high resolution electrospray mass spectrometry (HR-ESMS), and elemental analysis (experimental section and ESI †). Addition of one of the ligands (tripy, 2A-tripy, and 3A-tripy) to a solution of [Pd(CH3CN)4](BF4)2 in a 2:1 ratio resulted in the formation of the desired cages (Scheme 1). While the tripy and 3A-tripy containing cages formed instantaneously at room temperature, the formation of [Pd2(2A-tripy)4](BF4)4 required heating in DMSO solution at 50 °C for six hours to complete the assembly. The cages were characterised using 1 H and DOSY NMR spectroscopy, HR-ESMS, and elemental analysis, (experimental and ESI †). The 1 H NMR spectra (Figure 1 and ESI †) of the [Pd2(Ltripy)4] 4+ cages show a single set of peaks. The proton resonances due to the terminal pyridyl units of the cages (Hc-f) are shifted downfield (Δδ = 0.19-0.59 ppm) relative to the free tripy ligands, consistent with complexation to palladium(II) ions. Interestingly, the proton resonance of the 2-amino group in the [Pd2(2A-tripy)4](BF4)4 cage displays a very large (Δδ(HNH) = 1.56 ppm) shift relative to the free ligand (Figure 1) . Presumably, this large shift is caused by a combination of coordination to the palladium(II) ions and intra-ligand hydrogen bonding interactions between the amino groups on the adjacent ligands. Consistent with this postulate, the shift of the corresponding proton resonance in the [Pd2(3A-tripy)4](BF4)4 cage is much smaller (Δδ(HNH) = 0.81 ppm, ESI †). 11a, 11d, 12 and suggest that the palladium(II) cage species are stable in solution (ESI †). Mass spectra (HR-ESMS) of the [Pd2(Ltripy)4] 4+ cage systems in DMF-CH3CN solution obtained under pseudo cold-spray conditions displayed overlapping peaks due to [Pd2L4] 4+ and [PdL2] 2+ ions. Additionally, the spectrum of the 3A-tripy based cage displayed a peak due to the [Pd2(3A-tripy)4(BF4)2] 2+ ion.
After considerable effort (>50 crystallisations and data collections) the solid state structure of the [Pd2(2A-tripy)4](BF4)4 complex was obtained using X-ray crystallography (Figure 2 and Please do not adjust margins Please do not adjust margins ESI †). Small weakly diffracting X-ray quality crystals were generated by vapour diffusion of diethyl ether into a CH3CN solution of the [Pd2(2A-tripy)4](BF4)4 cage. Although the weak diffraction was, at least in part, due to the presence of multiple disordered solvent molecules and counter anions within the crystal lattice (vide infra), the cationic framework of the cage was readily identified (Figure 2 ). The solid state structure of the [Pd2(2A-tripy)4] 4+ cage confirms that the coordination of the 2-amino pyridyl units to the palladium(II) ions was monodentate through the pyridyl nitrogen as expected. 15 Additionally, the 2-amino units of the ligands are engaged in intra-ligand hydrogen bonding interactions (N---N 3.78(3) Å, N-H---N 2.94 Å, Figure 2b and ESI †) consistent with 1 H NMR data described above. In contrast to the [Pd2(tripy)4] 4+ cage, 16 the [Pd2(2A-tripy)4] 4+ cation adopts a more twisted structure in which the ligands of the 2A-tripy cages are significantly bent out of planarity and this appears to be caused by hydrogen bonding interactions between the amino groups on the exo faces of the architecture. This is quite different to what has been previously observed in the solid state structures of unsubstituted [Pd2(tripy)4] 4+ cations, these cages without the 2-amino groups all were found to adopt a lantern shape, with essentially planar tripy ligands. 11a, 11d, 12 The coordinated 2A-tripy ligand distorts in two ways: a swivelling of the coordinating pyridine rings relative to the principal rotation axis of the molecule (θ = 34.44° -34.64°, compared with θ = 3. 
Competition Experiments, Cisplatin Binding and Cytotoxicity Studies
The relative pKa values of 2-aminopyridine (6.82), 3-aminopyridine (6.04), and pyridine (5.23) indicate that 2-aminopyridine is the most basic ligand. 17 Evidence that 2-aminopyridine was also the strongest nucleophile was obtained using the palladium(II)-N-heterocyclic carbene (NHC) probe system developed by Huynh and coworkers (Table 1 and ESI †). 18 Consistent with the pKa values, the probe complexes indicated that 2-aminopyridine (161.2 ppm) is a stronger donor than the 3-aminopyridine (159.8 ppm) which is a stronger donor than pyridine (159.3 ppm). The chemical shift observed for the 2-aminopyridine ligand is very similar to that previously reported for N-methylimidazole (161.1 ppm) 18b suggesting that the donor strength of these ligands are similar. To allow direct comparison to the literature pKa values (Table 2 ) and for synthetic convenience 11a we have examined the probe complexes of the simpler pyridine rather than the tripyridyl ligands. However, these pyridine model systems can serve as proxies for their respective tripyridyl ligands (2A-tripy, 3A-tripy, tripy) and provide indirect experimental evidence for the donor properties of the tripy ligands because the steric and electronic changes on going from the pyridine to tripy ligands are the same across the series. Thus the model complexes provide a qualitative ranking of the substituents effects present in the tripy ligands and strongly suggest that the donor properties of the tripyridyl ligands follow the order 2A-tripy > 3A-tripy > tripy.
The kinetic stability of the [Pd2(Ltripy)4] 4+ architectures in the presence of common biological nucleophiles (Cl -, his and cys) was determined using 1 H NMR competition experiments (Table 1 and ESI †). Time-course 1 H NMR competition experiments were carried out in 3:2 d6-DMSO/D2O where 3 mM solutions of each cage were treated with 8 equivalents of tetramethylammonium chloride or 4 equivalents of his or cys. Under these conditions the unsubstituted [Pd2(tripy)4] 4+ cage was rapidly decomposed by all the nucleophiles. The half-life for the decomposition of the [Pd2(tripy)4] 4+ complex with his was 18 minutes. Despite the [Pd2(3A-tripy)4] 4+ architecture containing the slightly more electron rich 3A-tripy ligand the cage was still quickly decomposed by each of the nucleophiles. However, the t1/2 were subtly increased against all the nucleophiles (for his t1/2 = 25 mins) suggesting that the enhanced ligand donor properties of the 3A-tripy ligand does lead to increased cage stability relative to the unsubstituted system.
The [Pd2(2A-tripy)4] 4+ cage displayed markedly higher stability against all the nucleophiles studied. The half-lives for the 2A-tripy cage decomposition against each nucleophile were all over 2 hrs, whereas the corresponding t1/2 for the other cages were all less than 30 mins. 2A-tripy is only a modestly stronger donor ligand than the 16 The guest molecules are rotated 180° with respect to each other; hydrogen bonds between the guests and cage (N-H···NPy and Cl···H-CPy) as well as a metal-metal interaction between the platinum atoms of the guests were observed (Fig. 3a) . 11d, 16b, 19b A similar 1 H NMR experiment with cisplatin and [Pd2(3A-tripy)4] 4+ indicated that the 3-amino substituted cage is also able to bind cisplatin in solution, albeit more weakly (Δδ = 0.07 ppm for Hc, Figure 4c and d) than the parent [Pd2(tripy)4] 4+ cage. Conversely, 1 H NMR spectra of the [Pd2(2A-tripy)4] 4+ cage in the presence of cisplatin acquired in either deuterated CH3CN or DMF solvents displayed no shifts relative to the free cage indicating that the 2-amino substituted cage is not able to bind cisplatin. We have previously shown that cisplatin binding is very weak 12 and that subtle changes to the size, steric profile and electronic properties of the cage cavity 21 are enough to completely turn off cisplatin binding. Presumably, the lack of cisplatin binding in this system can be ascribed to two factors. Firstly, the presence of the eight amino group on the exo faces of the cage has caused a twisting of the architecture (as indicated in the crystal structure, Fig. 3 , and discussed and listed in Table 1 ). This twisting subtly alters both the size of the cisplatin binding cavity and the orientations of the hydrogen-bond acceptors and donors groups within the cage cavity, weakening the interaction between the host and the cisplatin guest. Secondly, the electron donating 2-amino units push electron density back onto the terminal pyridyl rings of the tripy ligand. This would reduce the polarisation of the acidic Hc protons of the pyridyl unit, weakening the hydrogen bonding interaction with chloride ligands of the cisplatin guest. These effects, in concert, appear to be enough to fully circumscribe the already weak cisplatin-cage interaction. 22 . We have previously shown that a more kinetically robust and hydrophobic [Pd2(La)4] 4+ helicate (La = 1,3-bis(1-hexyl-1H-1,2,3-triazol-4-yl)benzene) was considerably more cytotoxic (IC50 = 6 and 6.9 µM) against both the A549 and MDA-MB-231 cell lines. 11a Additionally, Yoshizawa and co-workers have recently reported that a hydrophobic [Pd2(Lb)4] 4+ cage (Lb = 3,3'-((4,5,6-tris(2-methoxyethoxy)-1,3-phenylene)bis(anthracene-10,9-diyl))dipyridine) is highly cytotoxic (IC50 = 1.8 and 1.9 µM) against HL-60 and SKW-3 cancer cell lines. 23 Thus it is presumed that low cytotoxicity of the systems described here is connected to the combination of both high kinetic lability and the more hydrophilic nature of the [Pd2(Ltripy)4] 4+ architectures and ligands.
Conclusions
Two amino substituted tripyridyl 2,6-bis(pyridin-3-ylethynyl)pyridine (tripy) ligands (with amino groups either in the 2-(2A 4+ architectures the half-lives of the systems against the stronger nucleophiles were still modest (t1/2 = 2-3 hrs). Furthermore, the subtle structural changes in the most stabilised cage, [Pd2(2A-tripy)4] 4+ were found to completely destroy the ability of the system to bind cisplatin. Thus, it appears that in order to exploit these types of metallosupramolecular cage architectures as drug delivery vectors, systems assembled from more kinetically inert metals ions such as Pt(II) 4h and Ru(II) 4e-g and Co(III) 25 will be required. Efforts to generate more robust systems, composed of kinetically inert metal ions, capable of binding drug molecules are underway.
Experimental General
Unless otherwise stated, all reagents were purchased from commercial sources and used without further purification. 2,5- 11a 28.5 ± 2.6 6.9 ± 0.9 89.8 ± 10.7 6.0 ± 0.6 ----
Please do not adjust margins
Please do not adjust margins pyridine, 26 5-iodo-2-aminopyridine, 6a the dimeric dibromobis(benzimidazolin-2-ylidene)dipalladium(II) complex, 27 and trans-dibromo(1,3-diisopropylbenzimidazolin-2-ylidene)(pyridine)palladium(II) 18b were synthesised according to literature procedures. Solvents were laboratory reagent grade. Petroleum ether refers to the fraction of petrol boiling in the range 40-60 °C, isopropyl alcohol (IPA), methanol (CH3OH), dichloromethane (CH2Cl2), ethylenediaminetetraacetate (EDTA), ethynyltrimethylsilane (TMS-acetylene), tetrahydrofuran (THF), dimethyl sulfoxide (DMSO), dimethylformamide (DMF). 1 H and 13 C NMR spectra were recorded on either a 400 MHz Varian 400-MR or Varian 500 MHz AR spectrometer. Chemical shifts are reported in parts per million and referenced to residual solvent peaks (CDCl3: 1 H δ 7.26 ppm, 13 C δ 77.16 ppm; CD3CN: 1 H δ 1.94, 13 C δ 1.32, 118.26 ppm, d6-DMSO: 1 H δ 2.50 ppm; 13 C δ 39.52 ppm). Coupling constants (J) are reported in Hertz (Hz). Standard abbreviations indicating multiplicity were used as follows: m = multiplet, q = quartet, t = triplet, dt = double triplet, d = doublet, dd = double doublet, s = singlet, br = broad. Full 1 H and 13 C NMR spectra, together with structural labelling are included in the ESI. IR spectra were recorded on a Bruker ALPHA FT-IR spectrometer with an attached ALPHA-P measurement module. Microanalyses were performed at the Campbell Microanalytical Laboratory at the University of Otago. Electrospray mass spectra (ESMS) were collected on a Bruker micrOTOF-Q spectrometer.
Synthesis of 5-iodopyridin-2-acetamide (1)
A solution of 5-iodopyridin-2-amine (2.5 g, 11.4 mmol) in triethylamine (10 mL) and CH2Cl2 (50 mL) was degassed with N2 for 15 minutes. Acetic anhydride (10.7 mL, 110 mmol) was added and the mixture was stirred at room temperature for 18 hours. After removal of solvents under vacuum, the crude mixture was dissolved in 3:1 CHCl3/IPA (150 mL), and washed with saturated aqueous NaHCO3 solution (2 x 75 mL), and brine (75 mL). The organic layer was dried over MgSO4, filtered and the solvent removed under vacuum. Column chromatography on silica (1:19 acetone/CH2Cl2) gave the product as a brown solid (2.3 g, 8.8 mmol, 77% 
Synthesis of N-(5-((trimethylsilyl)ethynyl)pyridin-2-yl)acetamide (2)
A round bottom flask containing 1 (1.00 g, 3.82 mmol), CuI (0.07 g, 0.38 mmol) and Pd(PPh3)2Cl2 (0.19 g, 0.27 mmol) was purged with N2. triethylamine (20 mL) was added via syringe and the solution was degassed with N2 for 15 minutes. After adding TMS-acetylene (0.68 g, 0.93 mL, 6.87 mmol) via syringe, the reaction was heated at reflux under N2 for 48 hours. The solvent was removed under vacuum, and the resulting solid was taken up in 3:1 CHCl3/IPA (40 mL). The solution was stirred with aqueous 0.1 M EDTA/NH4OH solution (40 mL) for 1.5 hours. After washing with aqueous 0.1 M EDTA/NH4OH (50 mL) and brine (100 mL), the organic layer was dried with Na2SO4, filtered, and the solvent removed under vacuum. The solid was purified through column chromatography on silica (1:19 Acetone/CH2Cl2), giving the product (0.86 g, 3.72 mmol, 97%). 1 3243, 2955 , 2161 , 1697 , 1579 , 1526 , 1380 , 1303 , 1246 , 1030 H, 7.14; N, 11.35%. Found: C, 61.94; H, 7.29 ; N, 11.35%.
Synthesis of 5-ethynylpyridin-2-amine (3)
A solution of 2 (0.63 g, 2.70 mmol) and NaOH (1.08 g, 27.0 mmol) in methanol (30 mL) was heated at reflux for 1.5 hours before removal of solvent under vacuum, with the resultant residue taken up in 3:1 CHCl3/IPA (100 mL) and washed with water (100 mL) and brine (100 mL). After drying with Na2SO4 and filtration, the solvent was removed under vacuum, and purification through column chromatography on silica (1:8 acetone/CH2Cl2) gave the product as a brown solid (0.22 g, 1.90 mmol, 70%). 1 H NMR (500 MHz, CDCl3, 298 K) δ: 8.22 (1H, dd, J = 2.2 Hz, 0.8 Hz, Hc), 7.53 (1H, dd, J = 8.6 Hz, 2.3 Hz, Hb), 6.46 (1H, dd, J = 8.6 Hz, 0.8 Hz, Ha), 4.69 (2H, br, HNH), 3.06 (s, Hd). 13 
Synthesis of of N-(5-((trimethylsilyl)ethynyl)pyridin-3-yl)acetamide (4)
A glass tube containing diisopropylamine (7 mL) degassed with N2 was charged with 5-bromopyridin-3-amine (500 mg, 2.89 mmol), CuI (55 mg, 0.29 mmol), Pd(dppf)2Cl2 (85 mg, 0.17 mmol) and TMSacetylene (1.173 mL, 852 mg, 8.67 mmol) against a positive N2 flow. The tube was sealed and stirred at 60 o C for 72 hours. 3:1 CHCl3/IPA (100 mL) and aqueous 0.1 M EDTA/NH4OH solution (100 mL) were added and the mixture stirred for one hour. The organic layer was washed with water (50 mL) and brine (50 mL), dried over Na2SO4, filtered, and the solvent was removed under vacuum. The resultant solid was purified by column chromatography (1:8 acetone/CH2Cl2) to give the product as a brown solid (512 mg, 2.71 mmol, 94%). 1 H NMR (500 MHz, CDCl3, 298 K) δ: 8.10 (1H, d, J = 1.5 Hz, Hc), 8.01 (1H, d, J = 2.7 Hz, Ha), 7.04 (1H, dd, J = 2.7 Hz, 1.7 Hz, Hb), 0.25 (9H, s, Hd). 13 C NMR (125 MHz, CDCl3, 298 K) δ: 142.9 (Cc), 141.9, 136.8 (Ca), 124.1 (Cb), 120.3, 101.9, 97.6, 0.0 (Cd) . HR ESI-MS (MeOH) m/z = 191.10 [M + H] + (calc. for C10H15N2Si, 191.10). Anal. calcd. for C10H14N2OSi: C, 63.11; H, 7.41; N, 14.62%; found: C, 63.40; H, 7.48; N, 14.62%. IR: ν (cm -1 ) 3327, 3295, 3162, 2147 N, 14.62%. IR: ν (cm -1 ) 3327, 3295, 3162, , 1585 N, 14.62%. IR: ν (cm -1 ) 3327, 3295, 3162, , 1424 N, 14.62%. IR: ν (cm -1 ) 3327, 3295, 3162, , 1329 N, 14.62%. IR: ν (cm -1 ) 3327, 3295, 3162, , 1245 .
Synthesis of 5-ethynylpyridin-3-amine (5)
A solution of 4 (0.43 g, 2.3 mmol) in methanol (30 mL) with Na2CO3 (0.48 g, 4.5 mmol) was stirred at room temperature for 1 h. After filtration, the solvent was removed under vacuum, and the resultant solid was purified by column chromatography on silica (1:8 acetone/CH2Cl2) to give the product as a brown solid (0.25 g, 2.1 mmol, 96%). 1 H NMR (500 MHz, CDCl3, 298 K) δ: 8. 13 (1H, d, J = 2.7 Hz, Hc), 8.05 (1H, d, J = 2.7 Hz, Ha), 7.06 (1H, dd, J = 2.7 Hz, 2.7 Hz, Hb), 3.71 (2H, br, HNH), 3.14 (1H, s, Hd) . 13 C NMR (125 MHz, CDCl3, 298 K) δ: 143.0 (Cc), 141.8, 137.1 (Ca), 124.0 (Cb), 119.1, 80.7, 79.8 (Cd) . IR: ν (cm -1 ) 3328, 3295, 3163, 3020, 2148 3328, 3295, 3163, 3020, , 1644 3328, 3295, 3163, 3020, , 1585 3328, 3295, 3163, 3020, , 1424 3328, 3295, 3163, 3020, , 1329 3328, 3295, 3163, 3020, , 1246 H, 5.37; N, 22.60%. Found: C, 70.96; H, 5.14; N, 22.80% . Mass spectral analysis was not successful for this compound.
Synthesis of tripy
A round bottom flask containing (2,6-dibromopyridin-4-yl)methanol (336 mg, 1.26 mmol), 3-ethynylpyridine (325 mg, 3.15 mmol) , CuI (24 mg, 0.12 mmol) and Pd(PPh3)2Cl2 (35 mg, 0.05 mmol) was purged with N2, before addition of triethylamine (25 mL) and dry THF (25 mL) . The reaction was stirred in the absence of light for 24 hours. CH2Cl2 (50 mL) and aqueous 0.1 M EDTA/NH4OH solution (100 mL) were added and the mixture stirred at room temperature for 2 hours. After extraction into CH2Cl2 (2 x 100 mL), the combined organic layers were washed with brine (100 mL), dried over MgSO4, and then filtered. The solvent was removed under vacuum. Column chromatography (2:3 CH2Cl2/acetone) gave the product as a colourless solid (280 mg, 0.90 mmol, 71%). 1 H NMR (500 MHz, CD3CN, 298 K) δ: 8.81 (2H, dd, J = 2.1 Hz, 0.8 Hz, Hc), 8.61 (2H, dd, J = 4.9 Hz, 1.7 Hz, Hf), 7.98 (2H, ddd, J = 7.9 Hz, 2.2 Hz, 1.7 Hz, Hd), 7.58 (2H, t, J = 0.9 Hz, Hb), 7.41 (2H, ddd, J = 7.9 Hz, 4.9 Hz, 0.9 Hz, He), 4.67 (2H, dt, J = 5.9 Hz, 0.8 Hz, Ha), 3.55 (1H, t, J = 5.9 Hz, HOH). 13 3204, 3032, 2923 3204, 3032, , 2213 3204, 3032, , 1685 3204, 3032, , 1596 3204, 3032, , 1547 3204, 3032, , 1475 3204, 3032, , 1415 3204, 3032, , 1189 3204, 3032, , 1076 3204, 3032, , 1023 H, 4.49; N, 12.90%. Found: C, 76.70; H, 4.49; N, 13 .06 %.
Synthesis of 2A-tripy
In a round bottom flask, diisopropylamine (20 mL) and THF (20 mL) were degassed with N2, before addition of 3 (400 mg, 3.39 mmol), (2,6-dibromopyridin-4-yl)methanol (362 mg, 1.35 mmol), CuI (25 mg, 0.14 mmol) , and Pd(PPh3)2Cl2 (38 mg, 0.050 mmol) against a positive N2 flow. The solution was heated at 50 o C for 48 hours. After removal of the solvent under vacuum, the resultant solid was taken up in 3:1 CHCl3/IPA (150 mL) and aqueous 0.1 M EDTA/NH4OH solution (50 mL) and stirred for 40 minutes. The organic layer was washed with brine, dried with Na2SO4, filtered and then the solvent was removed under vacuum. Purification of the resultant solid on a silica column deactivated with 3:97 triethylamine/CH2Cl2 (0.5/4.5/95 then 1/9/90 saturated aqueous NH4OH solution/MeOH/ CH2Cl2) gave the product as a brown solid (364 mg, 1.07 mmol, 79%). 1 H NMR (500 MHz, d6-DMSO, 298 K) δ: 8.18 (2H, dd J = 2.3 Hz, 0.5 Hz, Hc), 7.57 (2H, dd, J = 8.6 Hz, 2.3 Hz, Hd), 7.42 (2H, s, Hb), 6.55 (4H, s, HNH), 6.49 (2H, dd, J = 8.6 Hz, 0.6 Hz, He), 5.51 (1H, t, J = 5.8 Hz, HOH), 4.54 (2H, d, J = 5.7 Hz, Ha). 13 C NMR (500 MHz, 298 K) δ: 159.7, 153.0, 152.0 (Cc), 142.9, 139.7 (Cd), 122.6 (Cb), 107.7 (Ce), 104.9, 88.8, 88.0, 60.9 (Ca C20H16N5O, 342.14) . IR: ν (cm -1 ) 3307, 3145, 2920 , 2201 , 1670 , 1634 , 1593 , 1543 , 1505 , 1393 , 1171 , 1140 , 1055 , 1016 H, 4.38; N, 20.02%. Found: C, 69.12; H, 4.51; N, 20 .33%.
Synthesis of 3A-tripy
In a round bottom flask, diisopropylamine (20 mL) and THF (20 mL) were degassed with N2, before 5 (365 mg, 3.09 mmol), (2,6-dibromopyridin-4-yl)methanol (275 mg, 1.03 mmol), CuI (20 mg, 0.10 mmol), and Pd(PPh3)2Cl2 (36 mg, 0.05 mmol) were added against a positive N2 flow. The solution was heated at 40 o C for 48 hours. After removal of the solvent under vacuum, the resultant solid was taken in 3:1 CHCl3/IPA (150 mL) and aqueous 01. M EDTA/NH4OH solution (50 mL) and stirred for 40 minutes. The organic layer was washed with brine (100 mL), dried with Na2SO4, filtered, and then the solvent was removed under vacuum. Purification of the resultant solid in a silica column deactivated with 3:97 triethylamine/CH2Cl2 (0.5/4.5/95 then 1/9/90 saturated aqueous NH4OH solution/MeOH/ CH2Cl2) gave the product as a brown solid (197 mg, 0.58 mmol, 56% 3211, 3097, 2976, 2921, 2852, 2220, 1685, 1595, 1545, 1483, 1420, 1043, 1027 . Anal. calcd. for C80H52B4F16N12O4Pd2•3H2O: C, 51.67; H, 3.14; N, 9.04%. Found: C, 51.87; H, 3.09; N, 8.71%.
Synthesis of [Pd2(2A-tripy)4](BF4)4
A solution of 2A-tripy (40 mg, 0.12 mmol) and [Pd(CH3CN)4](BF4)4 (26 mg, 0.060 mmol) in 1.5 mL d6-DMSO in a tube was purged with N2 and was heated at 50 o C for 6 hours. Diethyl ether (30 mL) was added and the solution shaken vigorously. After decanting the liquid portion, the precipitate was suspended in CH2Cl2 (5 mL) and isolated by filtration. After washing with CH2Cl2 (5 mL), the solid was dried under vacuum at 60 o C for 4 days to give the product as a red solid (32 mg, 0.017 mmol, 57%). 1 H NMR (500 MHz, d6-DMSO, 298 K) δ: 8.77 (8H, d, J = 1.6 Hz, Hc), 8.11 (8H, s, HNH), 7.84 (8H, dd, J = 8.9 Hz,
X-ray crystallography [Pd2(2A-tripy)4](BF4)4
Yellow block crystals of [Pd2(2A-tripy)4](BF4)4 were grown by vapour diffusion of diethyl ether in a solution of MeCN. X-ray data were collected at 100(1) K on an Agilent Technologies Supernova system using Cu Kα radiation with exposures over 1.0o, and data were treated using CrysAlisPro 28 software. The structure was solved using Sir-97 29 and weighted full-matrix refinement on F2 was carried out using SHELXL-97 30 running within the WinGX package 31 . All nonhydrogen atoms were refined anisotropically. Hydrogen atoms were placed in calculated positions and refined using a riding model. The structure was solved in the primitive tetragonal space group P4/m and refined to an R1 value of 14.4%. The asymmetric unit contains two half ligands and two quarter occupancy palladium ions. The counter-anions and solvent molecules present in the solvent lattice were severely disordered and could not be appropriately modelled. The SQUEEZE routine within PLATON was employed to resolve this problem, resulting in ten void spaces (total of 460 electrons), variously assigned to tetrafluoroborate anions (8 in total), H2O (5 in total) and MeCN (3 in total) solvent molecules (total of 444 electrons), as described below. Despite repeated efforts (>50 crystallisations and data collections over a two year period) to crystallise the compound, the most suitable candidate was small and a poor diffractor. The data quality is poor, with two A alerts (a large Hirshfield difference and high MainMol Ueq compared to neighbours) and many B alerts, and we emphasise that metric data cannot be reliably extracted from the structure and should be treated with caution. However, the connectivity of the cationic framework is readily apparent. The methylene alcohol substituents from the four neighbouring cages in the lattice interpenetrate the cavity of each cage (Figure 3 and ESI) , interpenetrating groups shown in spacefilling mode (yellow, green, blue and pink) and preclude cisplatin encapsulation in the solid state. Around the coordinating pyridine rings, the amino groups form a hydrogen bonding network. SQUEEZE details and crystallographic parameters can be found in the ESI †.
